双特异性抗体治疗复发难治多发性骨髓瘤研究进展  

Progress of bispecific antibodies for relapsed/refractory multiple myeloma

作　　者：颜可泰 林全德 宋永平[2] Yan Ketai;Lin Quande;Song Yongping(Department of Hematology,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Hematology Institute of Henan Province,Zhengzhou 450008,China;Department of Hematology,First Affiliated Hospital of Zhengzhou University,Zhengzhou 450008,China)

机构地区：[1]郑州大学附属肿瘤医院,河南省肿瘤医院血液科,河南省血液病研究所,郑州450008 [2]郑州大学第一附属医院血液科,郑州450008

出　　处：《白血病．淋巴瘤》2024年第2期86-90,共5页Journal of Leukemia & Lymphoma

基　　金：中原青年拔尖人才(ZYYCYU202012163);河南省医学科技攻关计划省部共建重点项目(SBGJ202302026)。

摘　　要：近年来,包括靶向B细胞成熟抗原(BCMA)×CD3和G蛋白偶联孤儿受体C类第5组成员D(GPRC5D)×CD3在内的双特异性抗体(BsAb)用于治疗复发难治多发性骨髓瘤(RRMM)患者进行了广泛的研究。新药Teclistamab(BCMA×CD3)于2022年成为首个获得美国食品药品管理局(FDA)批准治疗RRMM的BsAb,埃纳妥单抗(Elranatamab)也于2023年获得批准。靶向BCMA×CD3的BsAb包括Alnuctamab、WVT078、ABBV-383、Linvoseltamab和F182112以及靶向GPRC5D×CD3的Talquetamab和LBL-034目前正在临床试验中进行评估。结合第65届美国血液学会年会报告,对BsAb治疗RRMM的研究进展进行报道。In recent years,bispecific antibodies(BsAb),including targeting B cell maturation antigen(BCMA)×CD3 and G protein-coupled orphan receptor class C group 5 member D(GPRC5D)×CD3,have been extensively studied for relapsed/refractory multiple myeloma(RRMM)patients.Teclistamab(BCMA×CD3)was the first BsAb approved for RRMM in 2022 by Food and Drug Administration(FDA),and elranatamab was approved in 2023.BsAb targeting BCMA×CD3 including alnuctamab,WVT078,ABBV-383,linvoseltamab,and F182112,as well as talquetamab and LBL-034 targeting GPRC5D×CD3 are currently being evaluated in clinical trials.Combining with the reports in the 65th Annual Meeting of the American Society of Hematology(ASH),this paper reviews the progress of BsAb in treatment of RRMM.

关 键 词：多发性骨髓瘤 抗体 双特异性 免疫疗法 

分 类 号：R733.3[医药卫生—肿瘤]